Loading
Anthony Davies - Dark Horse Consulting

Anthony Davies

Founder & CEO, Dark Horse Consulting

Anthony founded Dark Horse Consulting in 2014, bringing his decades of leadership experience in product, process, and manufacturing development to CGT companies in need of guidance. His extensive network within the biotechnology industry allowed him the privilege of hand-picking the exceptional team of consultants working at Dark Horse, chosen for their top-notch performance, broad abilities, and unique expertise.

Anthony’s responsibilities as Chief Executive Officer and Managing Partner include defining the strategic growth and focus of the practice, team building, liaising with key clients, and developing business for the company. He is a highly sought-after keynote speaker and chair of national and international conferences and seminars, known for his provocative, thoughtful, and sometimes contrarian presentations. Dr. Davies also holds a position as Chair of the DHC Board of Directors.

Prior to the founding of Dark Horse Consulting, Anthony served as a senior executive for multiple publicly traded and privately held companies, building a reputation for innovation, dedication, and competency.

A certified Six Sigma Champion, Anthony’s industry roles included:

  • Capricor Therapeutics, as Chief Technology Officer. His responsibilities included development and expansion of the company’s cardiovascular therapeutics portfolio: including, but not limited to, in-house and in-licensed stem cell and peptide products.
  • Geron, where Anthony was VP of Product Development. He led the process development, technical operations, pilot plant, analytical development, and cGMP manufacturing functions and was responsible for all CMC-related regulatory filings, including the first-ever IND to secure FDA clearance for initiation of clinical testing of an hESC-derived product.
  • Onyx Pharmaceuticals, where after critical contributions to the development of the oncology drugs Nexavar® and Ibrance®, Anthony built manufacturing teams for the adenovirus gene therapy ONYX-015, running a multi-thousand litre, pre-commercial process for this first-in-class product.
Sessions